Loading organizations...
Alladapt Immunotherapeutics is a Menlo Park, California-based clinical-stage biopharmaceutical company developing prescription oral immunotherapies for patients with IgE-mediated food allergies. The pre-revenue biotechnology firm focuses on its lead investigational candidate, ADP101, which is designed to simultaneously treat allergies to single or multiple major food groups. The company recently presented positive efficacy and safety data from its Phase 1/2 Harmony clinical trial evaluating this specific multi-food allergy treatment. To advance its clinical trials, manufacturing capabilities, and pipeline expansion, the enterprise has secured over $170 million in total funding, including a $119 million financing round in June 2022. This capital was provided by a syndicate of institutional investors featuring Enavate Sciences, Novartis Venture Fund, Gurnet Point Capital, Third Rock Ventures, and Bain Capital Life Sciences. Alladapt Immunotherapeutics was founded in 2018 by Ashley Dombkowski and Kari Nadeau.
Alladapt Immunotherapeutics has raised $349.0M across 4 funding rounds.
Alladapt Immunotherapeutics has raised $349.0M in total across 4 funding rounds.
Alladapt Immunotherapeutics has raised $349.0M in total across 4 funding rounds.
Alladapt Immunotherapeutics's investors include Himani Bhalla, Jim Momtazee, AllerFund, Sophie P. Kornowski, Pharm. D, MBA, Novartis, Heath Lukatch, George Montgomery, Andreessen Horowitz, FJ Labs, Red Tree Venture Capital, Uncork Capital, Xfund.
Alladapt Immunotherapeutics has raised $349.0M across 4 funding rounds. Most recently, it raised $50.0M Debt in August 2022.
Alladapt Immunotherapeutics is a private, clinical-stage biopharmaceutical company developing prescription therapeutics for IgE-mediated food allergies, primarily through oral immunotherapy.[1][2][4][5] Its lead product, ADP101, is an investigational broad-spectrum oral immunotherapy targeting proteins from nine key food groups responsible for ~90% of severe allergic reactions, serving children and adults with single or multiple food allergies.[1][2][5] The company addresses the critical problem of managing life-threatening food allergies, where current options are limited to avoidance or unapproved therapies, by aiming to desensitize patients and reduce reaction severity. Alladapt has raised ~$179 million in funding, including a $119 million oversubscribed round in 2022, signaling strong growth momentum amid rising food allergy prevalence.[2][5]
Founded in 2018 in Menlo Park, California, Alladapt Immunotherapeutics emerged from the need for effective food allergy treatments, co-founded by CEO Ashley Dombkowski and Kari Nadeau, a prominent allergist formerly at Stanford and now at Harvard.[2][3] Dombkowski, with expertise in biotech operations, partnered with Nadeau's clinical research on oral immunotherapy to create a company focused on broad-spectrum solutions rather than single-allergen therapies.[3] Early traction came from developing ADP101 and launching pivotal trials like the Phase 1/2 Harmony Study (randomized, double-blind, placebo-controlled) and its open-label Encore extension, building on Gurnet Point Capital's founding investment.[5] By 2022, an oversubscribed $119 million round from Enavate Sciences (Patient Square Capital), Novartis, and others validated its progress.[5]
Alladapt rides the surging food allergy therapeutics wave, where prevalence has doubled in recent decades, driving demand for disease-modifying treatments beyond epinephrine auto-injectors.[1][5] Timing aligns with regulatory progress (e.g., FDA approvals for peanut OIT like Palforzia) and investor interest in immunology, as seen in its $119M raise amid a biotech funding rebound.[5] Market forces favoring Alladapt include expanding IgE-mediated allergy pipelines, competition from Xolair-like therapies, and global needs for multi-allergen solutions in a $20B+ allergy market.[3] It influences the ecosystem by advancing oral immunotherapy standards, potentially enabling combo therapies and reducing ER visits, while partnering with heavyweights like Novartis accelerates validation.[5]
Alladapt is poised for Phase 3 trials and potential BLA submission post-Harmony data, with ADP101 eyeing approval as a first broad OIT by late 2020s if endpoints hit.[5] Trends like AI-driven allergy prediction, personalized dosing, and combo immunotherapies will shape its path, especially as polysensitized patients grow. Its influence could expand via acquisitions (noted investor "partial recovery" hints at exit potential) or partnerships, solidifying oral immunotherapy as a cornerstone for food allergy management—transforming a daily fear into a treatable condition.[3][5] This positions Alladapt as a leader in a high-stakes biotech niche with blockbuster potential.
